Take our Depression Test

Find a therapist to heal from trauma

A review/meta-analysis found MDMA-assisted therapy improves PTSD symptoms, but evidence certainty is low.

Positive trials establish lasting remission, adequate safety, and effectiveness in ordinary clinical practice.

VA and independent investigators are testing MDMA with different therapies, populations, and dosing.

FDA approval for now is uncertain.

Posttraumatic stress disorder (PTSD) is a potentially disabling disorder affecting approximately 8% of U.S. adults over their lifetime. Military veterans have even greater PTSD risks; as high as 21% of Gulf War veterans experience PTSD. I reported that MDMA-assisted psychotherapy may improve PTSD symptoms in adults. But how certain are we? That’s the central finding of an October 2026 Neuropsychopharmacology review by current Stanford Ph.D. student Brooke Sevchik and her former colleagues at the University of Pennsylvania. They rated overall evidence as low certainty.

The investigators analyzed six randomized trials involving 286 participants. They found MDMA-assisted therapy produced greater short-term improvement than control treatment. The pooled analysis found remission from PTSD was more than twice as likely with MDMA-assisted therapy. Impressive.

But questions remain about the overall quality of clinical trials due to blinding (subjects aren’t supposed to know if they received the test drug or placebo, but with drugs like MDMA, they usually do know) and remission at the end of trials. All six trials shared one sponsor, the Multidisciplinary Association for Psychedelic Studies (MAPS). While it bravely kept the field alive, the trials used closely related MAPS-associated psychotherapy protocols. So, these were not six independent replications.

Sevchik’s analysis found no statistically significant improvement in depression (often accompanying PTSD), although a separate meta-analysis reported broader benefits. The investigators also created an open database that can be updated as new evidence appears. Good. Conclusions should change when evidence changes.

Why Did the FDA Initially Say No to MDMA?

Two Phase 3 trials reported favorable outcomes, but the FDA declined approval in August 2024. Concerns included inadequate blinding, potential expectancy bias, aspects of psychotherapy delivery, and questions about safety and the reliability of efficacy estimates. Positive results were not enough to meet FDA standards.

But the Presidential Executive Order gave another chance to MDMA to resolve questions that remain about lasting recovery and also trial quality, particularly blinding and influence on improvement ratings. Participants receiving MDMA recognize its unmistakable psychoactive effects, while those receiving placebo may guess they received a sugar pill. The April 2026 presidential initiative accelerating psychedelic research adds momentum, but not evidence. Executive orders cannot substitute for randomized trials.

Resilient Pharmaceuticals, formerly Lykos, reportedly resubmitted its application to the FDA in August 2026. A resubmission is another chance to convince the FDA to approve the drug.

Why Might MDMA Help People With PTSD?

People with PTSD may experience intrusive memories of traumatic events years later. Sometimes the danger feels immediate, as though they are back at the original trauma site. Patients may avoid reminders of trauma, difficult conversations, and sometimes treatment itself.

MDMA increases serotonin signaling and affects dopamine, norepinephrine, and brain circuits involved in fear, emotional processing, and social reward. It may reduce fear and make patients more receptive to psychotherapy.

Although Oxytocin is commonly associated with childbirth and........

© Psychology Today